A New Hope for Patients with Advanced Gastric and Pancreatic Cancers

A groundbreaking new CAR-T cell therapy for advanced gastrointestinal cancers is expected to become available in China in the first half of 2026, marking a major step forward in cancer treatment. Jiahui International Cancer Center will be among the leading medical institutions offering access to this innovative therapy for eligible patients.

The therapy, known as satri-cel (CT041), is the world’s first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric (stomach) and pancreatic cancers. 

A New Era in Cancer Treatment

CAR-T therapy is a highly personalized treatment that uses a patient’s own immune cells, reprogrammed to recognize and attack cancer cells with precision. Unlike traditional therapies, CAR-T cells can expand inside the body and continue to fight cancer over time. 

While CAR-T has already transformed outcomes in blood cancers, this new therapy represents a major breakthrough in treating solid tumors, where effective options have historically been limited.

Promising Clinical Results

Clinical studies conducted in China have demonstrated encouraging outcomes for patients with advanced gastric and gastroesophageal cancers:

Objective response rate (ORR): ~41%, significantly higher than standard treatments More than 10x improvement vs. conventional therapies in some comparisons Progression-free survival extended to ~4.7 months vs. ~1.7 months with standard care 

These results have been presented at leading international conferences and published in top-tier medical journals, highlighting the global significance of this therapy. 

Addressing a Major Unmet Need

Advanced gastric and pancreatic cancers remain among the most difficult cancers to treat, with limited effective options in later lines of therapy and poor survival outcomes. 

This CAR-T therapy offers a new treatment pathway for patients who have exhausted conventional options.

Treatment Overview

Patients undergoing CAR-T therapy typically follow these steps:

Cell Collection – Patient’s immune (T) cells are collected Cell Engineering – Cells are modified to target cancer-specific markers Cell Expansion – Engineered cells are multiplied in a specialized lab Reinfusion – CAR-T cells are infused back into the patient to attack tumors 

The treatment is conducted under strict clinical protocols in specialized centers.

Availability for International Patients

Jiahui International Cancer Center will be offering access to this advanced therapy for eligible international patients, supported by:

Multidisciplinary oncology teams International patient coordination services English-speaking medical staff Comprehensive treatment and follow-up care

Who May Benefit

This therapy may be suitable for patients who:

Have advanced or metastatic gastric or gastroesophageal cancer Have received at least two prior lines of treatment Show Claudin18.2-positive tumors Meet clinical eligibility criteria 

Each patient will undergo a detailed medical evaluation to determine suitability.

Looking Ahead

This therapy represents a milestone in oncology, opening the door for CAR-T treatments beyond blood cancers and into solid tumors.

Ongoing research is exploring broader applications, including earlier-stage treatment and additional tumor types.

Contact & Referral Information

International patients and referring physicians can contact the International Office at Jiahui Health for: 

Teleconsultation appointment Medical record review Eligibility assessment Treatment planning and travel support 

Contact the International Office

Email: internationaloffice@jiahui.com
WhatsApp: +852 4619 1904